In CAR-T-cells, the extracellular domain ScFv is responsible for redirecting the specificity of CTLs to the malignant cells and can be designed according to specific antigens such as CD19 expressed in B-cell acute lymphocyte leukemia, chronic lymphocyte leukemia, and lymphoma [7, 52–55]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.